The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Therapeutic Proteins and Oral Vaccines-Global Market Insights and Sales Trends 2024
Synopsis
Therapeutic proteins are engineered in the laboratory for pharmaceutical use. They include non-covalent binders, enzymes and albumin and therefore have a wide range of treatment applications. Oral vaccines are biologically prepared products, which provide active acquired immunity to diseases. There are currently oral vaccines targeting cholera, polio, rotavirus, smallpox and yellow fever, among others. Oral vaccines comprise an agent resembling the disease-causing microorganism, such as a live attenuated or killed viral particle or the micro-organisms toxins or surface proteins.
The global Therapeutic Proteins and Oral Vaccines market size is expected to reach US$ 634.7 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Therapeutic Proteins and Oral Vaccines in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Therapeutic Proteins and Oral Vaccines market. Therapeutic Proteins, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Therapeutic Proteins and Oral Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Therapeutic Proteins and Oral Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Therapeutic Proteins and Oral Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Therapeutic Proteins and Oral Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Therapeutic Proteins and Oral Vaccines covered in this report include Abbott, Amgen, Biogen, Eli Lilly and Company, Roche, Johnson and Johnson, Merck, Novo Nordisk and Pfizer, etc.
The global Therapeutic Proteins and Oral Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott
Amgen
Biogen
Eli Lilly and Company
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Serum Institute of India
Emergent Biosolutions
TransAlgae
MigVax
Lumen Bioscience
Global Therapeutic Proteins and Oral Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Therapeutic Proteins and Oral Vaccines market, Segment by Type:
Therapeutic Proteins
Oral Vaccines
Global Therapeutic Proteins and Oral Vaccines market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Therapeutic Proteins and Oral Vaccines companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Therapeutic proteins are engineered in the laboratory for pharmaceutical use. They include non-covalent binders, enzymes and albumin and therefore have a wide range of treatment applications. Oral vaccines are biologically prepared products, which provide active acquired immunity to diseases. There are currently oral vaccines targeting cholera, polio, rotavirus, smallpox and yellow fever, among others. Oral vaccines comprise an agent resembling the disease-causing microorganism, such as a live attenuated or killed viral particle or the micro-organisms toxins or surface proteins.
The global Therapeutic Proteins and Oral Vaccines market size is expected to reach US$ 634.7 million by 2029, growing at a CAGR of 5.9% from 2023 to 2029. The market is mainly driven by the significant applications of Therapeutic Proteins and Oral Vaccines in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Therapeutic Proteins and Oral Vaccines market. Therapeutic Proteins, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Oral Vaccines segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Therapeutic Proteins and Oral Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Therapeutic Proteins and Oral Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Therapeutic Proteins and Oral Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Therapeutic Proteins and Oral Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Therapeutic Proteins and Oral Vaccines covered in this report include Abbott, Amgen, Biogen, Eli Lilly and Company, Roche, Johnson and Johnson, Merck, Novo Nordisk and Pfizer, etc.
The global Therapeutic Proteins and Oral Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Abbott
Amgen
Biogen
Eli Lilly and Company
Roche
Johnson and Johnson
Merck
Novo Nordisk
Pfizer
Sanofi
Serum Institute of India
Emergent Biosolutions
TransAlgae
MigVax
Lumen Bioscience
Global Therapeutic Proteins and Oral Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Therapeutic Proteins and Oral Vaccines market, Segment by Type:
Therapeutic Proteins
Oral Vaccines
Global Therapeutic Proteins and Oral Vaccines market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Therapeutic Proteins and Oral Vaccines companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Therapeutic Proteins and Oral Vaccines
1.1 Therapeutic Proteins and Oral Vaccines Market Overview
1.1.1 Therapeutic Proteins and Oral Vaccines Product Scope
1.1.2 Therapeutic Proteins and Oral Vaccines Market Status and Outlook
1.2 Global Therapeutic Proteins and Oral Vaccines Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Therapeutic Proteins and Oral Vaccines Market Size by Region (2018-2029)
1.4 Global Therapeutic Proteins and Oral Vaccines Historic Market Size by Region (2018-2023)
1.5 Global Therapeutic Proteins and Oral Vaccines Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Therapeutic Proteins and Oral Vaccines Market Size (2018-2029)
1.6.1 North America Therapeutic Proteins and Oral Vaccines Market Size (2018-2029)
1.6.2 Europe Therapeutic Proteins and Oral Vaccines Market Size (2018-2029)
1.6.3 Asia-Pacific Therapeutic Proteins and Oral Vaccines Market Size (2018-2029)
1.6.4 Latin America Therapeutic Proteins and Oral Vaccines Market Size (2018-2029)
1.6.5 Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size (2018-2029)
2 Therapeutic Proteins and Oral Vaccines Market by Type
2.1 Introduction
2.1.1 Therapeutic Proteins
2.1.2 Oral Vaccines
2.2 Global Therapeutic Proteins and Oral Vaccines Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Therapeutic Proteins and Oral Vaccines Historic Market Size by Type (2018-2023)
2.2.2 Global Therapeutic Proteins and Oral Vaccines Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Type (2018-2029)
3 Therapeutic Proteins and Oral Vaccines Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Therapeutic Proteins and Oral Vaccines Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Therapeutic Proteins and Oral Vaccines Historic Market Size by Application (2018-2023)
3.2.2 Global Therapeutic Proteins and Oral Vaccines Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Therapeutic Proteins and Oral Vaccines Revenue Breakdown by Application (2018-2029)
4 Therapeutic Proteins and Oral Vaccines Competition Analysis by Players
4.1 Global Therapeutic Proteins and Oral Vaccines Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Therapeutic Proteins and Oral Vaccines as of 2022)
4.3 Date of Key Players Enter into Therapeutic Proteins and Oral Vaccines Market
4.4 Global Top Players Therapeutic Proteins and Oral Vaccines Headquarters and Area Served
4.5 Key Players Therapeutic Proteins and Oral Vaccines Product Solution and Service
4.6 Competitive Status
4.6.1 Therapeutic Proteins and Oral Vaccines Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Abbott
5.1.1 Abbott Profile
5.1.2 Abbott Main Business
5.1.3 Abbott Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.1.4 Abbott Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.1.5 Abbott Recent Developments
5.2 Amgen
5.2.1 Amgen Profile
5.2.2 Amgen Main Business
5.2.3 Amgen Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.2.4 Amgen Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.2.5 Amgen Recent Developments
5.3 Biogen
5.3.1 Biogen Profile
5.3.2 Biogen Main Business
5.3.3 Biogen Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.3.4 Biogen Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.3.5 Eli Lilly and Company Recent Developments
5.4 Eli Lilly and Company
5.4.1 Eli Lilly and Company Profile
5.4.2 Eli Lilly and Company Main Business
5.4.3 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.4.4 Eli Lilly and Company Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.4.5 Eli Lilly and Company Recent Developments
5.5 Roche
5.5.1 Roche Profile
5.5.2 Roche Main Business
5.5.3 Roche Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.5.4 Roche Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.5.5 Roche Recent Developments
5.6 Johnson and Johnson
5.6.1 Johnson and Johnson Profile
5.6.2 Johnson and Johnson Main Business
5.6.3 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.6.4 Johnson and Johnson Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.6.5 Johnson and Johnson Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.7.4 Merck Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 Novo Nordisk
5.8.1 Novo Nordisk Profile
5.8.2 Novo Nordisk Main Business
5.8.3 Novo Nordisk Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.8.4 Novo Nordisk Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.8.5 Novo Nordisk Recent Developments
5.9 Pfizer
5.9.1 Pfizer Profile
5.9.2 Pfizer Main Business
5.9.3 Pfizer Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.9.4 Pfizer Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.9.5 Pfizer Recent Developments
5.10 Sanofi
5.10.1 Sanofi Profile
5.10.2 Sanofi Main Business
5.10.3 Sanofi Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.10.4 Sanofi Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.10.5 Sanofi Recent Developments
5.11 Serum Institute of India
5.11.1 Serum Institute of India Profile
5.11.2 Serum Institute of India Main Business
5.11.3 Serum Institute of India Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.11.4 Serum Institute of India Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.11.5 Serum Institute of India Recent Developments
5.12 Emergent Biosolutions
5.12.1 Emergent Biosolutions Profile
5.12.2 Emergent Biosolutions Main Business
5.12.3 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.12.4 Emergent Biosolutions Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.12.5 Emergent Biosolutions Recent Developments
5.13 TransAlgae
5.13.1 TransAlgae Profile
5.13.2 TransAlgae Main Business
5.13.3 TransAlgae Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.13.4 TransAlgae Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.13.5 TransAlgae Recent Developments
5.14 MigVax
5.14.1 MigVax Profile
5.14.2 MigVax Main Business
5.14.3 MigVax Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.14.4 MigVax Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.14.5 MigVax Recent Developments
5.15 Lumen Bioscience
5.15.1 Lumen Bioscience Profile
5.15.2 Lumen Bioscience Main Business
5.15.3 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Products, Services and Solutions
5.15.4 Lumen Bioscience Therapeutic Proteins and Oral Vaccines Revenue (US$ Million) & (2018-2023)
5.15.5 Lumen Bioscience Recent Developments
6 North America
6.1 North America Therapeutic Proteins and Oral Vaccines Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Therapeutic Proteins and Oral Vaccines Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Therapeutic Proteins and Oral Vaccines Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Therapeutic Proteins and Oral Vaccines Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Therapeutic Proteins and Oral Vaccines Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Therapeutic Proteins and Oral Vaccines Market Dynamics
11.1 Therapeutic Proteins and Oral Vaccines Industry Trends
11.2 Therapeutic Proteins and Oral Vaccines Market Drivers
11.3 Therapeutic Proteins and Oral Vaccines Market Challenges
11.4 Therapeutic Proteins and Oral Vaccines Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
